Background: Atypical hemolytic uremic syndrome (aHUS) is a rare cause of end-stage kidney disease and associated with poor outcomes after kidney transplantation from early disease recurrence. Prophylactic eculizumab treatment at the time of transplantation is used in selected patients with aHUS. We report a retrospective case note review describing transplant outcomes in patients with aHUS transplanted between 1978 and 2017, including those patients treated with eculizumab.
Methods: The National Renal Complement Therapeutics Centre database identified 118 kidney transplants in 86 recipients who had a confirmed diagnosis of aHUS. Thirty-eight kidney transplants were performed in 38 recipients who received prophylactic eculizumab. The cohort not treated with eculizumab comprised 80 transplants in 60 recipients and was refined to produce a comparable cohort of 33 transplants in 32 medium and high-risk recipients implanted since 2002. Complement pathway genetic screening was performed. Graft survival was censored for graft function at last follow-up or patient death. Graft survival without eculizumab treatment is described by complement defect status and by Kidney Disease: Improving Global Outcomes risk stratification.
Results: Prophylactic eculizumab treatment improved renal allograft survival ( P = 0.006) in medium and high-risk recipients with 1-y survival of 97% versus 64% in untreated patients. Our data supports the risk stratification advised by Kidney Disease: Improving Global Outcomes.
Conclusions: Prophylactic eculizumab treatment dramatically improves graft survival making transplantation a viable therapeutic option in aHUS.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065821 | PMC |
| http://dx.doi.org/10.1097/TP.0000000000004355 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Thrombosis in Paroxysmal Nocturnal Hemoglobinuria (PNH): From Pathogenesis to Treatment.
Int J Mol Sci
November 2024
Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.
Paroxysmal Nocturnal Hemoglobinuria (PNH) constitutes a rare bone marrow failure syndrome characterized by hemolytic anemia, thrombotic events (TEs), and bone marrow aplasia of variable degrees. Thrombosis is one of the major clinical manifestations of the disease, affecting up to 40% of individuals with PNH. Venous thrombosis is more prevalent, affecting mainly unusual sites, such as intrabdominal and hepatic veins.
View Article and Find Full Text PDFManagement of paroxysmal nocturnal hemoglobinuria with low-level hemolysis in pregnancy- a report of two cases.
Ann Hematol
November 2024
Department of Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.
Article Synopsis
- Pregnant women with paroxysmal nocturnal hemoglobinuria (PNH) face high risks of serious blood clots, but eculizumab, a complement inhibitor, can help reduce these risks and improve pregnancy outcomes.
- This study examines two pregnant patients with PNH showing low-level hemolysis, managed solely with preventive anticoagulation and no complement inhibition.
- Both patients had successful pregnancies without thromboembolic issues, suggesting that careful monitoring and anticoagulation might be a viable management approach for certain PNH cases during pregnancy, though more research is necessary.
Complement system activation: bridging physiology, pathophysiology, and therapy.
Intensive Care Med
November 2024
Department of Intensive Care, Raymond Poincaré Hospital, AP-HP, Garches, France.
The complement system is a set of over 50 proteins that constitutes an essential part of the innate immune system. Complement system activation involves an organized proteolytic cascade. Overactivation of complement system activation is the main pathogenic mechanism of several diseases and contributes to the manifestations of many other conditions.
View Article and Find Full Text PDFKidney Transplantation in Patients With aHUS: A Comparison of Eculizumab Prophylaxis Versus Rescue Therapy.
Transplantation
July 2024
National Renal Complement Therapeutics Centre, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, United Kingdom.
Article Synopsis
- The study compares the effectiveness and safety of eculizumab prophylaxis versus rescue therapy for kidney transplant recipients with atypical hemolytic uremic syndrome (aHUS), analyzing data from Dutch and UK patient cohorts.
- Results indicated similar graft survival rates between Dutch patients receiving rescue therapy and UK patients on prophylaxis, with Dutch patients showing slightly better outcomes but not significantly different.
- The findings suggest that in patients with lower genetic risk for recurrence, eculizumab rescue therapy may be as effective as prophylaxis without compromising graft survival.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!